Please provide your email address to receive an email when new articles are posted on . ApoA-I infusions may improve outcomes after acute heart attack for patients with multivessel CAD and ...
The aim of this review is to give an overview of lipid-related risk of atherosclerotic cardiovascular disease (ASCVD) beyond ...
National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.
The Framingham Heart Study identified lifestyle risk factors for heart disease, including smoking, high blood pressure, and high cholesterol. A recent study suggests testing for LDL, HScrp, and ...
LDL cholesterol, often called “bad” cholesterol, is significant in heart health. It’s a waxy substance in the blood that can accumulate in artery walls, forming plaque. This plaque buildup, known as ...
Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
Nanomedicine. 2014;9(1):105-120. Overall, HDL-based siRNA delivery possesses many attractive features, including ultra-small size, favorable surface properties (no PEGylation is required for achieving ...
New study explains why people with obesity are at a higher risk of developing cardiovascular disease
(Boston)—Obesity is a public health problem worldwide that currently affects more than 40% of adults in the U.S. Alarmingly, more than 9% of the U.S. population had severe (Class 3) obesity in 2020, ...
Isabel Casimiro, MD, PhD, is an endocrinologist at the University of Chicago in Illinois. As a physician-scientist in molecular biology, she uses her research on diabetes, lipid disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results